24.50

0.45% 0.11

Beam Therapeutics Inc (BEAM)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BEAM? Forum Prognose

Schlusskurs vom Vortag:

$24.39

Offen:

$25

24-Stunden-Volumen:

1.50M

Relative Volume:

0.76

Marktkapitalisierung:

$2.53B

Einnahmen:

$164.01M

Nettoeinkommen (Verlust:

$-65.04M

KGV:

-35.66

EPS:

-0.687

Netto-Cashflow:

$-383.84M

1W Leistung:

+0.95%

1M Leistung:

-16.35%

6M Leistung:

-0.65%

1J Leistung:

-4.26%

1-Tages-Spanne:

$24.21

$25.48

1-Wochen-Bereich:

$23.44

$25.48

52-Wochen-Spanne:

$20.23

$38.26

Beam Therapeutics Inc Stock (BEAM) Company Profile

Firmenname

Beam Therapeutics Inc

Sektor

Healthcare (1064)

Branche

Biotechnology (595)

Telefon

857-327-8775

Adresse

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Mitarbeiter

522

Twitter

Nächster Verdiensttermin

2026-11-03

Neueste SEC-Einreichungen

BEAM's Discussions on Twitter

Compare BEAM vs VRTX, MRNA, REGN, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BEAM Beam Therapeutics Inc	24.50	2.51B	164.01M	-65.04M	-383.84M	-0.687
VRTX Vertex Pharmaceuticals Inc	504.73	133.37B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	190.01	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	735.20	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.21	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.64	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-20	Eingeleitet	Canaccord Genuity	Buy
2025-10-09	Eingeleitet	Jefferies	Buy
2025-03-28	Hochstufung	BofA Securities	Neutral → Buy
2025-03-10	Hochstufung	Scotiabank	Sector Perform → Sector Outperform
2025-01-29	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2024-11-06	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-07-23	Eingeleitet	H.C. Wainwright	Buy
2024-01-29	Hochstufung	JP Morgan	Neutral → Overweight
2023-12-15	Herabstufung	BofA Securities	Buy → Neutral
2023-12-08	Herabstufung	Jefferies	Buy → Hold
2023-10-20	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2023-10-20	Herabstufung	Leerink Partners	Outperform → Market Perform
2023-03-21	Eingeleitet	Bernstein	Mkt Perform
2023-02-01	Eingeleitet	Cantor Fitzgerald	Overweight
2022-12-20	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2022-12-13	Eingeleitet	Citigroup	Buy
2022-06-17	Eingeleitet	BMO Capital Markets	Market Perform
2022-04-28	Eingeleitet	Credit Suisse	Neutral
2022-01-05	Eingeleitet	Guggenheim	Buy
2021-10-19	Eingeleitet	SVB Leerink	Outperform
2021-09-24	Fortgesetzt	Stifel	Buy
2021-09-10	Eingeleitet	BofA Securities	Buy
2021-05-11	Eingeleitet	Redburn	Buy
2021-05-04	Eingeleitet	RBC Capital Mkts	Sector Perform
2021-03-01	Herabstufung	Barclays	Overweight → Equal Weight
2021-02-16	Eingeleitet	Wells Fargo	Overweight
2021-01-29	Herabstufung	JP Morgan	Overweight → Neutral
2021-01-06	Eingeleitet	Stifel	Hold
2020-08-05	Eingeleitet	William Blair	Outperform
2020-03-02	Eingeleitet	Barclays	Overweight
2020-03-02	Eingeleitet	JP Morgan	Overweight
2020-03-02	Eingeleitet	Jefferies	Buy
2020-03-02	Eingeleitet	Wedbush	Outperform

Alle ansehen

Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten

Oct 01, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc.BEAM - PR Newswire

Oct 01, 2026

Sep 30, 2026

Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative - Yahoo Finance

Sep 30, 2026

Beam says Chinese firm, Serapha stole trade secrets (BEAM) - Seeking Alpha

Sep 30, 2026

Three biotech updates, including accusations of theft and and a new lobbying leader - statnews.com

Sep 30, 2026

(BEAM) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Sep 30, 2026

Sep 29, 2026

Beam sues 2 biotechs, alleging theft of base editing trade secrets - BioPharma Dive

Sep 29, 2026

Beam Therapeutics Inc (NASDAQ: BEAM) Share Price, BEAM Stock News, BEAM Share Price & Updates - kalkine.ca

Sep 29, 2026

Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress (NASDAQ:BEAM) - Seeking Alpha

Sep 29, 2026

Sep 28, 2026

As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock - Barchart.com

Sep 28, 2026

Beam Says Scientist Stole Secrets for Her Chinese Rival Startup - Bloomberg Law News

Sep 28, 2026

Sep 27, 2026

PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits

Sep 27, 2026

Sep 26, 2026